Organization | Bay Area Retina Associates

Bay Area Retina Associates Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial

2006

NCT00390208

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2020

Timeline

NOW

Now

Alternative names

Bay Area Retina Associates | Physician | Roger Goldberg, M.D., MBA | Subhransu K. Ray, M.D., Ph.D.

Active Ingredients

Drugs in Phase 4 Trials (7)

aflibercept (zaltrap) (1 trial)

bevacizumab (avastin) (1 trial)

dexamethasone (2 trials)

ketorolac (acuvail) (1 trial)

ozurdex (1 trial)

ranibizumab (lucentis) (3 trials)

ropivacaine (naropin) (1 trial)

Drugs in Phase 2 Trials (3)

mifepristone (mifeprex) (1 trial)

urea (2 trials)

verteporfin (visudyne) (1 trial)

Drugs in Other Trials (3)

melatonin (1 trial)

vitamin c (1 trial)

zeolite (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Cataract (Phase 4)

Central Serous Chorioretinopathy (Phase 2)

Edema (Phase 4)

Macular Degeneration (Phase 2)

Macular Edema (Phase 4)

Pain, Postoperative (Phase 4)

Wet Macular Degeneration (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 9
# of Trial APIs: 13